scientific report 2017 1. oncology institute of southern ... · iosi oncology institute of southern...

4

Scientific Report 2017

1. Oncology Institute of Southern Switzerland (IOSI)

The Institute includes many of the cancer speciali-

sations within the EOC and is organised in a single

medical and administrative structure meeting pa-

tients’ needs transversally through the four public

Hospitals of Ticino. It was built based on the model

of the American Comprehensive Cancer Centers

but without the surgical component. Therefore,

the Institute is currently composed of five medi-

cal services: medical oncology, haematology, ra-

dio-oncology, palliative care and nuclear medicine.

Haematology, palliative care and nuclear medicine

also provide care and services for patients who do

not suffer from cancer.

In the past, the IOSI also had a clinical research

department and a laboratory research department.

During 2017 the laboratory research unit was

definitely separated from the IOSI in a facility

called Institute of Oncology Research, logisti-

cally located together with the Institute of Re-

search in Biomedicine in the centre of Bellinzona.

The Clinical Research Unit was also restructured

and is no longer a separate unit. It was decided

that each department will conduct clinical research

which will be centrally coordinated by an IOSI clini-

cal Research Unit (CRU) made up of study coordina-

tors and research nurses who will help perform the

clinical studies of all the departments. A separate

Unit for the development of new anticancer drugs

has existed for decades and continues its activity.

Although the IOSI performs research in different

types of cancer and also in non-oncological areas,

the Institute decided that in the next five years

it will mainly focus on lymphoproliferative diseas-

es, prostate cancer and new drug development.

Other topics of interest include breast can-

cer, gastrointestinal cancer and radiomics.

The following report shows the research activi-

ty of the five medical Services in the last year.

5

IOS

I O

ncol

ogy

Inst

itute

of

Sou

ther

n S

wit

zerl

and

1.1. Medical Oncology Service

Prof. Michele Ghielmini MD

Medical Director of the IOSI and Head Doctor

The medical oncology service boasts a long tradition in clinical research which mainly focussed on new

drug development, lymphomas and breast cancer in the past. It has now been decided that prostate can-

cer will also be a primary focus in the future.

As in the past, during 2017 clinical research was performed mostly in collaboration with other institutes,

first of all, with the Swiss Working Group for Clinical Cancer Research (SAKK) and more locally, with the

help of the EOC Research Found (ABREOC). Some studies are also carried out in collaboration with the

laboratories of the Institute of Oncology Research (IOR), but also with the Pathology Institute in Locarno

(ICP). For the new drug sector, some studies were carried out with drugs which had a preclinical develop-

ment in the IOR laboratories, a collaboration that was initiated by Prof. Franco Cavalli and was continued

by Prof. Cristiana Sessa who also retired this year. Her role was taken over by Dr Anastasios Stathis.

This area was mainly developed in collaboration with pharmaceutical industries.

Likewise for the lymphomas, the IOSI remains the main location for the International Extranodal Lym-

phoma Group (IELSG) whose director is Prof. Emanuele Zucca. Thanks to this close collaboration, many

publications could be completed including IOSI members.

Finally, Prof. Olivia Pagani, who is responsible for the breast unit, is also an influential member of the In-

ternational Breast Cancer Group (IBCSG) and the cooperative group BIG. This explains the high number

of international publications that IOSI authors produced.

Continuing the long-standing tradition of training abroad, several of our young doctors spent some time

in international institutions where they could carry out research and publish.

Peer reviewed publications in 2017

Enoiu M, Berardi S, Gargiulo P, Sessa C; Swiss

Group for Clinical Cancer Research (SAKK). Phase I trial of the oral smoothened inhibi-tor sonidegib in combination with paclitax-el in patients with advanced solid tumors.

Invest New Drugs. 2017 Dec;35(6):766-

772. doi: 10.1007/s10637-017-0454-z. Epub

2017 Mar 20. PubMed PMID: 28317088.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone

DP, Owen D, Camidge R, Narayanan V, Doebele

RC, Besse B, Remon-Masip J, Janne PA, Awad

MM, Peled N, Byoung CC, Karp DD, Van Den Heu-

vel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH,

Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR,

Riess JW, Velcheti V, Zeidler K, Diebold J, Früh

M, Michels S, Monnet I, Popat S, Rosell R, Kara-

chaliou N, Rothschild SI, Shih JY, Warth A, Muley

T, Cabillic F, Mazières J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multi-

center RET Registry.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi:

10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

Stathis A, Hess D, von Moos R, Homicsko

K, Griguolo G, Joerger M, Mark M, Acker-

mann CJ, Allegrini S, Catapano CV, Xyrafas A,

Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppen-

berger S, Oehlschlegel C, Bernhard J, Brauchli

P, Hess D, Mamot C, Munzone E, Pestalozzi B,

Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiess-

er K, Thürlimann B, von Moos R, Zaman K, Gol-

dhirsch A; Swiss Group for Clinical Cancer Re-

search (SAKK). Do all patients with advanced HER2 positive

6


breast cancer need upfront-chemo when re-ceiving trastuzumab? Randomized Phase III trial

SAKK 22/99.

Ann Oncol. 2017 Feb 1;28(2):305-312. doi:

10.1093/annonc/mdw622.

Voegeli M, Rondeau S, Berardi Vilei S, Lerch E,

Wannesson L, Pabst T, Rentschler J, Bargetzi M,

Jost L, Ketterer N, Bischof Delaloye A, Ghielmini M. Y(90) Ibritumomab tiuxetan (Y(90) -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to

chemotherapy: a feasibility trial (SAKK 37/05).

Hematol Oncol. 2017 Dec;35(4):576-583. doi:

10.1002/hon.2348. Epub 2016 Sep 28.

Zucca E, Conconi A, Martinelli G, Bouabdallah R,

Tucci A, Vitolo U, Martelli M, Pettengell R, Salles

G, Sebban C, Guillermo AL, Pinotti G, Devizzi L,

Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri

AJ, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei

M, Ponzoni M, Copie-Bergman C, Jack A, Campo E,

Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Sur-vival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

J Clin Oncol. 2017 Jun 10;35(17):1905-1912. doi:

10.1200/JCO.2016.70.6994. Epub 2017 Mar 29.

Main funding

ABREOC (internal competitive grant);

Swiss Group for Clinical Cancer Research (SAKK);

International Extranodal Lymphoma Study Group

(IELSG); International Breast Cancer Study Group

(IBCSG); Breast International Group (BIG); phar-

maceutical industries.

Awards 2017

A. Stathis

Pfizer award in oncology in 2017.

Promotion 2017

A. Stathis

Promoted to staff medical oncologist (Doctor -

Head of Service).

7

IOS

I O

ncol

ogy

Inst

itute

of

Sou

ther

n S

wit

zerl

and

1.2. Radiation Oncology Service

Antonella Richetti MD

Head Doctor

The research activity of our clinic heavily relies on the collaboration between several specialised teams,

involving medical doctors, physicists, radiation technologists and nurses. Teamwork is the keyword of our

clinical and research activity.

A special aspect of the scientific progress in our Radiotherapy Clinic is that it is largely the result of a

significant intellectual and technological collaboration with the EOC Service of Medical Physics.

A collection of clinical and technical information of patients is recorded in the dedicated database for the

most common tumours treated in our clinic.

Medical doctors are committed to different collaborations with national and international working groups

(SAKK, EORTC, e.g.) and work as teachers locally at the radiation technologist school (SSMT) and for

nurses at the school for specialised oncology and psycho-oncology (SUPSI); furthermore they take part

in international faculties of advanced courses in clinical oncology (ESO, ESTRO, Italian Universities). The

participation in clinical trials is divided into self-sponsored studies and multicenter trials. The former in-

clude: Mepitel to avoid skin toxicity in breast cancer RT (MC. Valli), Resection cavity radiosurgery in brain

metastases (ABREOC Brain RT 001 - G. Pesce), Radiosurgery in oligometastatic recurrence of prostate

cancer (ABREOC RT 002 - NC. Azinwi). The latter include: SAKK 15/12: early PCI with hippocampal spa-

ring in SCLC (G. Pesce); INT 48/14, HETECO: Health and economic outcomes of two different follow-up

strategies in effectively treated advanced head and neck cancer. A phase II trial (A. Richetti) and others

that are already summarised in previous reports and that continue patient enrolment.


Broglie MA, Stoeckli SJ, Sauter R, Pasce P, Re-

inhard A, de Leval L, Huber GF, Pezier TF, Solter-

mann A, Giger R, Arnold A, Dettmer M, Arnoux

A, Mèller M, Spreitzer S, Lang F, Lutchmaya M,

Stauffer E, Espeli V, Martucci F, Bongiovanni M,

Foerbs D, Jochum W. Impact of human papillomavirus on outcome in patients with oropharyngeal cancer treated with

primary surgery.

Head Neck. 2017 Oct;39(10):2004-2015. doi:

10.1002/hed.24865. Epub 2017 Jul 10.

Carrara M, Romanyukha A, Tenconi C, Mazzeo D,

Cerrotta A, Borroni M, Cutajar D, Petasecca M,

Lerch M, Bucci J, Richetti A, Presilla S, Fallai C,

Gambarini G, Pignoli E, Rosenfeld A. Clinical application of MOSkin dosimeters to rec-tal wall in vivo dosimetry in gynecological HDR

brachytherapy.

Phys Med. 2017 Sep;41:5-12. doi: 10.1016/j.

ejmp.2017.05.003. Epub 2017 May 9.

Pascale M, Azinwi NC, Marongiu B, Pesce G, St-

offel F, Roggero E. The outcome of prostate cancer patients treated with curative intent strongly depends on survival

after metastatic progression.

BMC Cancer. 2017 Sep 18; 17(1):651.

doi:10.1186/s12885-017-3617-6. PubMed

PMID: 28923109; PubMed Central PMCID:PMC

5604496.

Pellanda AF, De Bari B, Deniaud-Alexandre E,

Krengli M, Van Houtte P, Richetti A, Villà S, Gold-

berg H, Szutowicz-Zielinska E, Bolla M, Rutten H,

Van Eijkeren M, Poortmans P, Henke G, Anacak

Y, Chan S, Landmann C, Kirkove C, Scandolaro L,

Bernier J, Mirimanoff RO, Ozsahin M.

8


Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A rare Cancer Network study.

Chin J Cancer Res. 2017 Dec;29(6):521-532.

doi: 10.21147/j.issn.1000-9604.2017.06.06.

Yordanov K, Cima S, Richetti A, Pesce G, Martuc-

ci F, Azinwi NC, Valli MC. Concurrent chemoradiation with volumetric mod-ulated Arc therapy of patients treated for anal

cancer-acute toxicity and treatment outcome.

J Gastrointest Oncol. 2017 Apr;8(2):361-367.

doi: 10.21037/jgo.2017.03.09.

Main funding

Swiss Group for Clinical Cancer Research, SAKK

(SAKK 01/10, SAKK 09/10, SAKK 15/12, IBC-

SG 38-10); ABREOC (internal competitive grant)

(IOSI-RTO-001; IOSI-RTO-002); European Orga-

nisation for Research and Treatment of Cancer

(EORTC). INT 48/14 and IRMA study, no funding.

9

IOS

I O

ncol

ogy

Inst

itute

of

Sou

ther

n S

wit

zerl

and

1.3. Nuclear Medicine Service

Prof. Luca Giovanella MD, PhD

Head Doctor

Nuclear Medicine uses radiopharmaceuticals and technologically advanced equipment (gamma cameras,

SPET/CT and PET/CT tomographs) to carry out diagnostic tests (i.e. scintigraphy, SPECT, SPECT/CT

and PET/CT) in each area of clinical medicine and namely, oncology, cardiology, endocrinology, immunology

and neurology.

Moreover, some radiopharmaceuticals are used for the treatment of thyroid diseases [hyperthyroidism

and thyroid carcinomas], bone metastases, neuroendocrine tumours, lymphomas and inflammatory ar-

thropathies.

The Clinic is located at the Regional Hospitals of Bellinzona (San Giovanni) and Lugano (Civico). Both

sites are equipped with high-technology instruments (SPECT/CT gamma cameras, PET/CT tomographs)

and provide all nuclear medicine and hybrid-imaging procedures as well as treatments for thyroid diseases

(outpatients), bone metastases and arthropathies. The centre for in-patient radioisotopic therapies is

located at the Regional Hospital of Bellinzona and Valli (San Giovanni) (3 dedicated rooms).

The Clinic also includes:

• The EOC Competence Center for Thyroid Diseases [Director: Prof. Luca Giovanella] providing thyroid

consultations, diagnostic procedures (US, scintigraphy, fine-needle and core-needle biopsy) and

non-surgical therapies (drugs, radioiodine, US-guided alcohol injection and thermal treatments)

• The IOSI-IOR Unit for Molecular Imaging (Responsible physician: Dr Luca Ceriani) for the clinical and

basic research on molecular imaging applications in oncology.


Ceriani L, Martelli M, Conconi A, Zinzani PL, Ferreri

AJM, Botto B, Stelitano C, Gotti M, Cabras MG,

Rigacci L, Giovanella L, Zucca E, Johnson PWM. Prognostic model for primary mediastinal (thym-ic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Ex-tranodal Lymphoma Study Group (IELSG) 26 study.

Br J Haematol. 2017 Aug;178(4):588-591. doi:

10.1111/bjh.14728. Epub 2017 May 9.

Ceriani L, Martelli M, Gospodarowicy MK, Ri-

cardi U, Ferreri AJM, Chiappella A, Stelitano C,

Balzarotti M, Cabrera ME, Cunningham D, Guar-

ini A, Zinzani PL, Giovanella L, Johnson PWM,

Zucca E.

Positron Emission Tomography/Computed Tomog-raphy assessment after immunochemotherapy and irradiation using the Lugano Classification Criteria in the IELSG-26 study of Primary Medi-

astinal B-cell Lymphoma.

Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):42-

49. doi: 10.1016/j.ijrobp.2016.09.031. Epub

2016 Sep 28.

Piccardo A, Puntoni M, Bottoni G, Treglia G, Fop-

piani L, Bertoli M, Catrambone U, Arlandini A, Dib

B, Altrinetti V, Massollo M, Bossert I, Cabria M,

Bertagna F, Giovanella L. Differentiated thyroid cancer lymph-node re-lapse. Role of adjuvant radioactive iodine therapy

after lymphadenectomy.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):926-

934. doi: 10.1007/s00259-016-3593-0. Epub

2016 Dec 14.

10


Main funding


International Extranodal Lymphoma Study Group

(IELSG); ABREOC (internal competitive grant);

Roche Diagnostics GmbH; Brahms-Termofisher

GmbH; Theraclion SA.

11

IOS

I O

ncol

ogy

Inst

itute

of

Sou

ther

n S

wit

zerl

and

1.4. Palliative Care Service

Claudia Gamondi MD, MSc

Clinical Director

Palliative care involves looking after a patient and his family by adopting a global approach in order to

maintain or re-establish the best possible quality of life in an interdisciplinary way. Palliative care is pro-

vided by different healthcare professionals, such as doctors, nurses, psychologists and social workers,

all with highly specialised skills.

The Palliative and Supportive Care Clinic IOSI-EOC (CCPS), which can be found in all EOC Hospitals, has

the mission to promote this philosophy and disseminate the specific know-how of palliative care to ho-

spital teams through specialist consultation at a patient’s bedside, by developing the necessary training

programmes.

The Research Unit team of the Palliative Care Clinic includes Claudia Gamondi, MSc (responsible phy-

sician), Tanja Fusi-Schmidhauser, MD, MSc, Anna Oriani, MD and Yves Franzosi (part-time research

coordinator) and boasts national and international collaborations. Its main partners are: IOSI Oncology

Service, SUPSI, Haute École de la Santé Lausanne, Service de Soins Palliatifs (Palliative Care Service of

CHUV, Lausanne), International Observatory on End of Life Care (Lancaster, UK) and Istituto Nazionale

dei Tumori, INT (National Cancer Institute of Milan, Italy).


Bernard M, Strasser F, Gamondi C, Braunschweig

G, Forster M, Kaspers-Elekes K, Walther Veri S,

Borasio GD; SMILE consortium team. Relationship Between Spirituality, Meaning in Life, Psychological Distress, Wish for Hastened Death, and Their Influence on Quality of Life in

Palliative Care Patients.

J Pain Symptom Manage. 2017 Oct;54(4):514-

522. doi: 10.1016/j.jpainsymman.2017.07.019.

Epub 2017 Jul 15.

Delfine V, Bernasconi E, Bardelli D, Spataro V, Fu-

si-Schmidhauser T. Intractable Neck Pain in an Oncologic Palliative

Care Setting: Is Cancer Always the Answer?

J Pain Palliat Care Pharmacoter. 2017

Mar;31(1):43-44.

doi: 10.1080/15360288.2017.1279503. Epub

2017 Mar 1.

12


Main funding

Grant of Oncosuisse and Dr Claudia Gamondi re-

ceived a bursary for her PhD studies from the Got-

tfried und Julia Bangerter-Rhyner-Stiftung (CH).

Awards 2017

C. Gamondi, T. Fusi-Schmidhauser, D. Reinholz

Identification of patients with palliative care needs

is a public health priority: the implementation of a

screening tool in Switzerland.

Poster Prize at the 15th World Congress of the

European Association for Palliative Care, Madrid,

May 18th-20th, 2017.

13

IOS

I O

ncol

ogy

Inst

itute

of

Sou

ther

n S

wit

zerl

and

1.5. Haematology Service

Georg Stüssi MD, PD

Head Doctor

The Clinic for Haematology and the Laboratory of Experimental Haematology led by Dr Davide Rossi had

very positive development in 2017. Due to the initiative of Dr Rossi, but also thanks to the collaboration

of all physicians involved in the lymphoma and leukaemia treatment, we were able to start the collection

of liquid biopsies in virtually all patients with lymphoma, myeloma and chronic lymphatic leukaemia. This

biobank serves as a basis for current and future translational research activities. Moreover, several tri-

als conducted by the Haematology team were initiated in the last two years (IELSG46, IOSI-EMA-001,

IOSI-EMA-002, IOSI-EMA-003, IOSI-EMA-004 and IOSI-EMA-005).

The Clinic for Haematology and the Laboratory of Experimental Haematology received several grants

from the Swiss National Fund, Oncosuisse, European Research Council, ABREOC and other national and

international funding agencies amounting overall to 4 million CHF for the period 2016-2022.

In 2017, the Clinic for Haematology was also able to offer academic and company-sponsored clinical tri-

als for the majority of haematological disease entities. In particular, we were able to increase our study

activities for patients with chronic lymphatic leukaemia and elderly patients with acute myeloid leukaemia.

In this patient group, the IOSI is one of the major contributors in Switzerland.

In 2017, the translational research of the Laboratory of Experimental Haematology provided the first

evidence that plasma can be used as an accessible and real-time liquid biopsy for tracking genotype, clonal

evolution and measurable residual disease in aggressive lymphomas such as diffuse large B-cell lymphoma

and classical Hodgkin lymphoma.


Gaidano G, Rossi D. The mutational landscape of chronic lymphocytic leu-kemia and its impact on prognosis and treatment.

Hematology Am Soc Hematol Educ Program. 2017

Dec 8;2017(1):329-337. doi: 10.1182/asheduca-

tion-2017.1.329.

Rossi D, Diop F, Spaccarotella E, Monti S, Zanni

M, Rasi S, Deambrogi C, Spina V, Bruscaggin A,

Favini C, Serra R, Ramponi A, Boldorini R, Foà R,

Gaidano G. Diffuse large B-cell lymphoma genotyping on the

liquid biopsy.

Blood. 2017 Apr 6;129(14):1947-1957. doi: 10.1182/

blood-2016-05-719641. Epub 2017 Jan 17.

Rossi D, Gerber B, Stüssi G. Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocyt-

ic leukemia.

Leuk Lymphoma. 2017 Jul;58(7):1548-1560. doi:

10.1080/10428194.2016.1250264. Epub 2016 Nov 3.

Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis

A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan

XJ, Shanafelt T, Plevova K, Boudjogra M, Rossi

D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ,

Scarfo L, Stavroyianni N, Sudarikov A, Veronese

S, Tzenou T, Karan-Djurasevic T, Catherwood M,

Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C,

Pedersen LB, Mansouri L, Smedby KE, Chu CC,

14


Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson

G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin

L, Montillo M, Niemann C, Döhner H, Langerak

AW, Pospisilova S, Hallek M, Campo E, Chiorazzi

N, Maglaveras N, Oscier D, Gaidano G, Jelinek

DF, Stilgenbauer S, Chouvarda I, Darzentas N,

Belessi C, Davi F, Hadzidimitriou A, Rosenquist R,

Ghia P, Stamatopoulos K.

Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct

Immunogenetic Features and Clinical Outcomes.

Clin Cancer Res. 2017 Sep 1;23(17):5292-5301.

doi: 10.1158/1078-0432.CCR-16-3100. Epub

2017 May 23.

Main funding


Swiss National Science Foundation (SNSF); On-

cosuisse; ABREOC; European Research Council

(ERC).

15

IOS

I O

ncol

ogy

Inst

itute

of

Sou

ther

n S

wit

zerl

and

1.6. IOSI Nursing Service

Roberto Guggiari

Nurse Director

Over the last few years, nurses at the IOSI, as well as throughout the EOC, have developed additional

knowledge and skills to be able to offer high-quality professional services to their patients. Their appro-

ach refers to the “Relationship-based care” model that relies on the quality of the relationship between

nurses and patients. This model requires responsibility, accountability and investment in training and re-

search as essential conditions to meet the many health needs of patients more effectively and contribute

to their well-being.

Within an ever-changing healthcare system, the development of expertise in care is an essential element

to ensure skilled and individualised treatments and to promote a real multidisciplinary collaboration. To

facilitate these processes, research in the field of nursing is developing. The main purpose of investigation

in this area is to contribute to the development of knowledge in all areas where nurses must take their

decisions for the sake of patients and their families. Nursing research has specific purposes and contents

but is not different in methods compared to other research fields.

On this basis, a Nursing Research and Development Office was set up within the IOSI Nursing Service,

under the responsibility of Dario Valcarenghi (PhD).


Bonetti L, Cattalani M, Pacciani A, Angelini C,

Basile P, Currà MC, Evicelli E, Spotti D, Crisalide

L, Ledonne G.Percezione ed esperienza di studenti, assistenti di tirocinio e tutor universitari in relazione all’implementazione di una Dedicated Education Unit: una ricerca qualitativa con focus group. (students’, clinical nurse preceptors’ and academic tutors’ perception and experience in relation to the implementation of a Dedicated Education Unit: a qualitative study using focus

group).

Professioni Infermieristiche (Nursing professions).

2017; 70(3): 139-149. doi: 10.7429/

pi.2017.703139.

Cadorin L, Bagnasco A, Tolotti A, Pagnucci N, Sasso L. Developing an instrument to measure emotional behaviour abilities of meaningful learning through

the Delphi technique.

J Adv Nurs. 2017; 73(9): 2208-2218. doi:

10.1111/jan.13273. Epub 2017 Mar 9.

Wallhult E, Kenyon M, Liptrott S, Mank A, Nì

Chonghaile M, Babic A, Bijkerk J, Bompoint C,

Corbacioglu S, de Weijer R, Fink C, Marktel S,

Soni V, Sprenger S, Trigoso Arjona E, Mohty M. Management of veno-occlusive disease: the

multidisciplinary approach to care.

Eur J Haematol. 2017 Apr;98(4):322-329. doi:

10.1111/ejh.12840. Epub 2017 Feb 2.

16


Main funding

Mepitel film toward standard treatments for the

prevention and treatment of skin toxicity from ra-

diation therapy in the postoperative treatment of

breast cancer: project funded by Mölnlycke He-

althcare. It started in January 2016 and is still

ongoing.

Fatigue in cancer patients at the IOSI: ABREOC in

2014 (internal competitive grant). Mixed methods

study. It started in June 2016 and is still ongoing.

The Peripherally Inserted Central Catheters

(PICC) at the Ente Ospedaliero Cantonale (EOC):

use of a database as quality control of the pro-

cess: self-funded project.

It started in January 2016 and is still ongoing.

Utilization and complications of the vascular devi-

ces used at the IOSI (AVI, CVC, PICC): ABREOC

in 2016. It started in Winter 2017.

Awards 2017

D. Valcarenghi

Award for best oral nursing presentation at The

7th Research Day of Southern Switzerland 2017,

Lugano, 10th March 2017:

I Cateteri Centrali a Impianto Periferico (PICC):

bilancio di 4.5 anni di attività allo IOSI (Peripher-

al Implant (PICC) Central Catheters: a balance of

4.5 years of activity at the IOSI).

A. Babic

In appreciation of her invaluable contribution as

President of EBMT Nurse Group and a member of

the EBMT Scientific Council and Board of Associ-

ation from 2014-2017, by Prof. Mohamad Mohty;

Marseille 2017 on behalf of EBMT Board of Asso-

ciation and Scientific Council.

17

IOS

I O

ncol

ogy

Inst

itute

of

Sou

ther

n S

wit

zerl

and

scientific report 2017 1. oncology institute of southern ... · iosi oncology institute of southern...

Documents